Integris Medtech IPO
Market Sentiment
IPO Details
IPO Reservation
Financial Analysis
Financial Data
Financial Performance
| Metric | 31 Mar 2023 | 31 Mar 2024 | 31 Mar 2025 | 30 Jun 2025 |
|---|---|---|---|---|
| Revenue | 1,369.66 | 1,582.26 | 1,959.58 | 508.93 |
| Profit (PAT) | -40.54 | -4.88 | 70.68 | 267.57 |
| Total Assets | 2,553.87 | 2,989.20 | 3,641.34 | 4,019.62 |
Peer Comparison
| Company | EPS | P/E | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Integris Medtech This IPO | 5.82 | - | 1.84 | 316.09 | - |
| Laxmi Dental Limited | 6.07 | 53.95 | 16.09 | 37.71 | 239.11 Cr |
| Poly Medicure Limited | 34.13 | 56.02 | 12.26 | 278.46 | 1,669.83 Cr |
Strengths & Risks
- Revenue grew 24% in the latest reported year.
- Modest return on equity — 5%.
From this issue's live data. Not investment advice — read the RHP.
Company Information
Integris Medtech at a glance
From the company's description: “Founded in 2008, Integris Medtech is one of the leading global medical products and laboratory solutions providers in India.”
Integris Medtech is raising an undisclosed amount through an IPO on the BSE and NSE mainboard in the Pharmaceuticals sector. All of it is a fresh issue: there is no offer for sale, so every rupee raised goes to the company rather than to selling shareholders. Main stated uses of the fresh money: Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applic… (₹510 crore), The step-down Subsidiaries, namely, CPC Diagnostics Pvt.Ltd., Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Su… (₹416 crore) and The wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd. (Transhe… (₹93.87 crore).
Written from the issue's offer-document figures shown on this page. Not investment advice.
Company Contact Information
Integris Medtech Ltd., 1 st Floor, Metro Tower LSC, M.O.R Land, New Rajinder Nagar, North Delhi, New Delhi, 110060
Objects of the Issue
| Purpose | Amount (Cr) |
|---|---|
| Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: | 509.85 |
| The wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd. (Transhealth) ) and HaleMed Medical Pvt.Ltd. | 93.87 |
| The step-down Subsidiaries, namely, CPC Diagnostics Pvt.Ltd., Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd. | 415.98 |
| General Corporate Purposes | - |
Resources & Documents
IPO Documents
Draft Red Herring ProspectusIntegris Medtech IPO - Quick Take
Integris Medtech is preparing a mainboard offering in the pharmaceuticals sector. The Mainboard issue is scheduled to open for subscription on November 27, 2026 — 5 days from now.
The company operates in the pharmaceuticals space.
The issue is promoted by Evercure Holdings Pte.Ltd., Medicore Holdings Pte.Ltd., Gurmit Singh Chugh, Punita Sharma with Axis Capital Ltd, Citigroup Global Markets India Pvt Ltd, ICICI Securities Ltd, Iifl Securities Ltd acting as lead manager. Net proceeds will primarily be used towards repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties,… (Rs 510 crore) and the wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd… (Rs 94 crore).
On fundamentals, the company is posting revenue growth of 23.9%, a profit margin of 3.6%, return on equity of 5.4% in its most recent reported period. Listed peers in this segment include Laxmi Dental Limited (P/E 53.95x) and Poly Medicure Limited (P/E 56.02x) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
All figures below — GMP history, subscription tiers, financials and peers — are aggregated from public disclosures. Always apply through your own broker after reading the RHP.
Integris Medtech IPO: Lead Manager & Registrar Track Record
How the firms running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Integris Medtech itself, so they describe what came before it.
- 71% of 114 listings opened above the issue price; median listing-day move +6.8%.
- Average listing-day move across all 114 Mainboard listings we track: +13.6%.
| Firm | Other IPOs | Listed at / above issue | Avg move | Median |
|---|---|---|---|---|
| Axis Capital Ltd Lead manager | 23 23 MB · 0 SME | 89% 17 of 19 | +14.7% | +6.7% |
| Citigroup Global Markets India Pvt Ltd Lead manager | 6 6 MB · 0 SME | 67% 2 of 3 | +3.3% | +0.8% |
| ICICI Securities Ltd Lead manager | 22 22 MB · 0 SME | 70% 14 of 20 | +16.6% | +5.6% |
| Iifl Securities Ltd Lead manager | 1 1 MB · 0 SME | 100% 1 of 1 | +64.7% | +64.7% |
| KFin Technologies Limited Registrar | 101 56 MB · 45 SME | 81% 79 of 97 | Check allotment → | |
Recent listings managed by Axis Capital Ltd (5)
Best: Moneyview +63.6% · Weakest: Clean Max Enviro −8.8%
| IPO | Listed | Listing-day move |
|---|---|---|
| EAAA India Alternatives | 02 Nov 2026 | +0.6% |
| Jio Platforms | 28 Oct 2026 | +21.4% |
| Bonfiglioli Transmissions | 23 Oct 2026 | +0% |
| Moneyview | 01 Oct 2026 | +63.6% |
| NSE | 24 Sep 2026 | +0.8% |
Recent listings managed by Citigroup Global Markets India Pvt Ltd (3)
Best: Jio Platforms +21.4% · Weakest: Amagi Media Labs −12.2%
| IPO | Listed | Listing-day move |
|---|---|---|
| Jio Platforms | 28 Oct 2026 | +21.4% |
| NSE | 24 Sep 2026 | +0.8% |
| Amagi Media Labs | 21 Jan 2026 | −12.2% |
Recent listings managed by ICICI Securities Ltd (5)
Best: Tempsens Instruments +111.3% · Weakest: Turtlemint Fintech −11.3%
| IPO | Listed | Listing-day move |
|---|---|---|
| Jio Platforms | 28 Oct 2026 | +21.4% |
| Bonfiglioli Transmissions | 23 Oct 2026 | +0% |
| Runwal Enterprises | 05 Oct 2026 | +0.3% |
| NSE | 24 Sep 2026 | +0.8% |
| Hero Motors | 23 Sep 2026 | −2.3% |
Recent listings managed by Iifl Securities Ltd (1)
| IPO | Listed | Listing-day move |
|---|---|---|
| Orient Cables | 05 Oct 2026 | +64.7% |
A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.
Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.
Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.
Frequently Asked Questions
Integris Medtech IPO GMP — What It Means
No active grey market premium has been recorded for Integris Medtech IPO yet. GMP is an unofficial, dealer-quoted indicator of expected listing-day demand — not a guaranteed listing price — and it can change quickly once bidding opens.
See the full Integris Medtech GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
Same sector or same stage as Integris MedtechNo comments yet. Be the first to share your opinion!